Semaglutide for weight loss: separating fact from TikTok hype

What did @elgatoconpesas actually say?

Honestly, this one is difficult to fact-check in any meaningful way. The transcript captured from this video reads: "I'm not going to have this chicken for you. I'm going to bring you a bit of your mouth and then I'm going to get you." That is almost certainly a garbled auto-transcription, not an accurate rendering of what was said in Spanish. The hashtags point squarely at semaglutide, obesity, and nutrition, but the actual content of the claims made cannot be verified from this transcript alone.

Because the video has 828,600 views and sits in the GLP-1 category, the stakes of whatever was actually communicated are real. Spanish-language semaglutide content on TikTok reaches a significant and underserved audience that may have limited access to clinical guidance. What someone says in a high-reach video like this matters, even if the auto-transcription failed to capture it.

Does the science back this up?

We cannot evaluate the specific claims here because the transcript is unintelligible. What we can do is situate this video in the broader landscape of semaglutide misinformation, which is where most GLP-1 content on TikTok falls down. The science on semaglutide is actually quite strong, which makes the misinformation problem more frustrating, not less.

The STEP trials, published by Wilding et al. in 2021 in the New England Journal of Medicine, showed that 2.4 mg weekly semaglutide produced roughly 14.9% body weight reduction over 68 weeks in adults without diabetes. The SUSTAIN trials established its efficacy in type 2 diabetes. The mechanism, GLP-1 receptor agonism slowing gastric emptying and modulating appetite signaling in the hypothalamus, is well characterized. What the evidence does not support is the parade of TikTok claims around rapid weight loss, no dietary changes needed, or semaglutide as a permanent fix rather than a chronic treatment.

What did they get wrong (or right)?

We cannot assign accuracy or inaccuracy to a transcript that reads like machine noise. That is not a dodge, it is the honest answer. The auto-transcription failed, likely because the creator was speaking Spanish and the system defaulted to English output. Fact-checking a translation artifact is not fact-checking.

What we can flag is the category risk. GLP-1 content on TikTok skews heavily toward overpromising. A 2023 analysis by Southwick et al. published in Obesity found that a majority of popular TikTok GLP-1 videos contained at least one inaccurate or unsubstantiated claim. Common errors include conflating Ozempic, which is FDA-approved for type 2 diabetes, with Wegovy, approved for chronic weight management, presenting anecdotal weight loss timelines as typical, and minimizing side effects like nausea, pancreatitis risk, and muscle mass loss during rapid weight reduction.

What should you actually know?

If you found this video through a search on semaglutide or Ozempic, here is what the actual evidence says. Semaglutide works, but it works best as part of a structured clinical program, not as a standalone shortcut. The weight loss seen in trials was accompanied by dietary counseling and monitoring. Discontinuation studies, including Wilding et al. 2022 in Diabetes, Obesity and Metabolism, showed that most of the weight returns within a year of stopping the medication without lifestyle support in place.

Side effects are real and range from manageable gastrointestinal symptoms to, in rare cases, more serious concerns. The FDA has not established a confirmed causal link between semaglutide and thyroid C-cell tumors in humans, though the animal data prompted a black box warning. Anyone considering GLP-1 therapy should have that conversation with a licensed prescriber who reviews their full medical history, not a TikTok comment section.

• Semaglutide is not approved for cosmetic weight loss in people with a BMI under 27 with no weight-related comorbidities.
• Compounded semaglutide is not equivalent to FDA-approved Ozempic or Wegovy. Do not let anyone tell you otherwise.
• The evidence base for GLP-1 drugs is genuinely strong. The hype machine around them is not the same thing as that evidence base.